Abstracts Archive - Page 1385 of 2607 - ACR Meeting Abstracts

Abstract Number: 2982 • 2018 ACR/ARHP Annual Meeting
Normal Mortality of the Cobra Early Rheumatoid Arthritis Trial Cohort after 23 Years Follow up
Pomme Poppelaars¹, Lilian van Tuyl² and Maarten Boers^1,3, ¹Rheumatology, Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center | VU University Medical Center, Amsterdam, Netherlands, ³Epidemiology & Biostatistics, Epidemiology & Biostatistics | VU University Medical Center, Netherlands, Amsterdam, Netherlands
ACR abstractBackground/Purpose: Mortality in patients with rheumatoid arthritis (RA) is higher than in the general population. In most studies this becomes apparent only after more…
Abstract Number: 2983 • 2018 ACR/ARHP Annual Meeting
The Changing Faces of Rheumatoid Arthritis Patients at Presentation: A 20-Year Study
Nathalie Carrier¹, Sophie Roux², Ariel Masetto², Artur J deBrum Fernandes³, Patrick Liang⁴, Meryem Maoui⁵ and Gilles Boire⁴, ¹Centre intégré universitaire de santé et de services sociaux de l'Estrie -Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada, ²Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ³Medicine, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Bristol-Myers Squibb Canada., St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution of baseline demographic, clinical, serological and genetic characteristics of patients with incident RA over 20 years. Methods: Since July 1998,…
Abstract Number: 2984 • 2018 ACR/ARHP Annual Meeting
Lifestyle and MTX Use Are the Strongest Predictors of Not Achieving Remission in the First Year of Rheumatoid Arthritis: Results from the Canadian Early Arthritis Cohort (CATCH)
Susan J. Bartlett^1,2, Orit Schieir³, Marie-France Valois⁴, Carol Hitchon⁵, Louis Bessette⁶, Gilles Boire⁷, Carter Thorne⁸, Janet E. Pope⁹, Vivian P. Bykerk¹⁰, Edward C. Keystone¹¹, Diane Tin¹² and Glen Hazlewood¹³, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³McGill University, Montreal, ON, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ⁷Rheumatology Division, Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁸University of Toronto, Newmarket, ON, Canada, ⁹Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Implementation of RA guidelines have improved remission outcomes in RA; nevertheless 45% of early RA participants do not achieve remission in the first year.…
Abstract Number: 2985 • 2018 ACR/ARHP Annual Meeting
Achievement of Remission in Two Early Rheumatoid Arthritis Inception Cohorts Implementing Different Treat-to-Target Strategies
Vibeke Norvang^1,2, Gina Hetland Brinkmann^1,3, Joseph Sexton¹, Anna-Birgitte Aga¹, Siri Lillegraven¹, Till Uhlig^1,2, Tore Kvien^1,2, Maria Dahl Mjaavatten¹ and Espen A. Haavardsholm^1,2, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²University of Oslo, Oslo, Norway, ³Dept. of Rheumatology, Østfold Hospital, Grålum, Norway
Background/Purpose: Treat-to-target (T2T) has become a key element in the management of rheumatoid arthritis (RA). Several different measures exist to define the preferred treatment target…
Abstract Number: 2986 • 2018 ACR/ARHP Annual Meeting
The Impact of Exercise and Clinical Factors on Perceived Cognitive Function in Patients with Rheumatoid Arthritis: Results from a Prospective Cohort Study
Nancy A. Shadick¹, Christine K Iannaccone², Patricia Katz³, Gabriela L. Maica⁴, Jonathan Coblyn⁵, Michael E Weinblatt⁶ and Jing Cui⁷, ¹Rheumatology Immunology & Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Brigham and Women’s Hospital, Boston, MA, ³University of California San Francisco, San Francisco, CA, ⁴Department of Rheumatology, Allergy, and Immunology, Brigham and Women's Hospital, Boston, MA, ⁵Department of Rheumatology, Brigham & Womens Hospital, Boston, MA, ⁶Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁷Division of Medicine and Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Modifiable lifestyle factors such as inactivity and obesity contribute to cognitive decline in the general population, but little is known about how these factors…
Abstract Number: 2987 • 2018 ACR/ARHP Annual Meeting
RAPID Remission during the First Year in EARLY ACTIVE Rheumatoid Arthritis Is Associated with Better 5 YEARS Structural Damage Outcomes
Julie Legrand¹, Thomas Kirchgesner¹, Tatiana Sokolova², Bruno Vande Berg¹ and Patrick Durez², ¹Musculoskeletal Imaging Unit, Musculoskeletal Imaging Unit - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, ²Rheumatology, Rheumatology - Cliniques universitaires Saint-Luc - Université Catholique de Louvain - Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium
Background/Purpose: Remission is arguably the best and ultimate therapeutic goal in early rheumatoid arthritis (ERA). ERA patients (pts) who reach rapid and sustained remission are…
Abstract Number: 2988 • 2018 ACR/ARHP Annual Meeting
Characteristics and Outcomes in a Prospective Cohort of Patients with Aortitis Diagnosed Following Surgical Resection
Hart Goldhar¹, Mohamed Abdelrazek² and Nataliya Milman³, ¹Medicine, University of Ottawa, Ottawa, ON, Canada, ²Medical Imaging, University of Ottawa, Ottawa, ON, Canada, ³University of Ottawa Department of Medicine, University of Ottawa Division of Rheumatology, Ottawa, ON, Canada
Background/Purpose: Aortitis, characterized by inflammation of the aorta, is broadly divided into infectious and non-infectious aortitis (NIA); the latter group consists of a number of…
Abstract Number: 2989 • 2018 ACR/ARHP Annual Meeting
Cardiac Involvement in Systemic Vasculitis: A Retrospective Pathological Study
Olena Zimba¹ and Mykola Bahrii², ¹Department of Internal Medicine N2, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine, ²Department of Pathology and Forensic Medicine, Ivano-Frankivsk National Medical University, Ivano-Frankivsk, Ukraine
Background/Purpose: Even though clinically significant heart involvement is rare, cardiovascular complications are leading causes of death in systemic vasculitis (SV). The comprehensive analysis of histopathologic…
Abstract Number: 2990 • 2018 ACR/ARHP Annual Meeting
Do Polymyalgia Rheumatica Patients Have an Increased Risk of Cardiovascular Events?: A Matched-Control Study
Florencia Beatriz Mollerach¹, Marina Scolnik², Javier Rosa³, Nicolas Martin Marin Zucaro³ and Enrique R Soriano², ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina
Background/Purpose: Cardiovascular (CV) risk in chronic inflammatory diseases is increased. Polymyalgia Rheumatica (PMR) is an inflammatory condition that might have a prolonged course. Our objective…
Abstract Number: 2991 • 2018 ACR/ARHP Annual Meeting
Malignancies In Giant Cell Arteritis- A Population-Based Cohort Study
Pavlos Stamatis¹, Carl Turesson², Minna Willim³, Jan-Åke Nilsson⁴, Martin Englund⁵ and Aladdin Mohammad⁶, ¹Clinical Sciences, Rheumatology Lund, Lund University, Lund, Sweden, ²Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund, Lund University, Lund, Sweden, ⁴Department of Rheumatology, Skåne University Hospital, Malmö, Sweden, ⁵Clinical Sciences Lund, Clinical Epidemiology Unit, Lund University, Lund, Sweden, ⁶Department of Medicine, University of Cambridge, Cambridge, United Kingdom
Background/Purpose: To investigate the cancer risk in patients with biopsy-proven giant cell arteritis (GCA). Methods: The study population consisted of 830 patients (74 % women)…
Abstract Number: 2992 • 2018 ACR/ARHP Annual Meeting
Are Specific Vascular Symptoms in Takayasu’s Arteritis Reflective of Vascular Inflammation, Vascular Damage, or Both?
Despina Michailidou¹, Joel S. Rosenblum¹, Mark A. Ahlman², Jamie Marco³ and Peter C. Grayson⁴, ¹NIAMS, National Institute of Arthritis, Musculoskeletal and Skin Disease (NIAMS), Bethesda, MD, ²Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ³Radiology and Imaging Sciences National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients with Takayasu’s arteritis (TAK) can experience symptoms due to vascular inflammation or vascular damage. The study objective was to investigate whether specific vascular…
Abstract Number: 2993 • 2018 ACR/ARHP Annual Meeting
Vascular Involvement in Behcet’s Syndrome May be Associated with Subclinical Atherosclerosis
Emine USLU YURTERI¹, EVREN ÜSTÜNER², Murat TORGUTALP¹, Mucteba Enes YAYLA¹, Ilyas Ercan OKATAN¹, Ayse Bahar KELESOGLU DINCER¹, Serdar SEZER¹, Emine Gozde AYDEMIR GULOKSUZ¹, Tahsin Murat TURGAY¹, Gülay KINIKLI³ and Aşkın Ateş⁴, ¹Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine Department of Internal Medicine, Division of Rheumatology, ANKARA, Turkey, ²RADIOLOGY, ANKARA UNIVERSITY RADIOLOGY DEPARTMENT, ANKARA, Turkey, ³Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁴Department of Internal Medicine, Division of Rheumatology, Ankara University School of Medicine, Ankara, Turkey
Background/Purpose: Behçet's Syndrome (BS) is a vasculitic process which is characterized by recurrent oral and genital aphthous ulcerations, ocular, vascular, neurological, and gastrointestinal involvement .…
Abstract Number: 2994 • 2018 ACR/ARHP Annual Meeting
Costs Associated with Non-Medical Switching from Originator to Biosimilar Etanercept in Patients with Rheumatoid Arthritis in the UK
Kateryna Onishchenko¹, Stamatia Theodora Alexopoulos¹, Cinzia Curiale² and Miriam Tarallo², ¹Consulting at McCann Health, London, United Kingdom, ²Pfizer, Rome, Italy
Background/Purpose: To estimate the cost impact of non-medical switching from originator etanercept (ETN) to biosimilar ETN in patients with rheumatoid arthritis (RA) in the UK.…
Abstract Number: 2995 • 2018 ACR/ARHP Annual Meeting
Healthcare Cost of Potential Glucocorticoid-Associated Adverse Events in Patients with Giant Cell Arteritis
Jennie H. Best¹, Amanda Kong², David Smith², Ibrahim Abbass¹ and Margaret Michalska¹, ¹Genentech, Inc., South San Francisco, CA, ²IBM Watson Health, Bethesda, MD
Background/Purpose: To quantify the healthcare expenditures associated with oral glucocorticoids-related-adverse events (OGCs-AEs), among patients in the US with giant cell arteritis (GCA) using claims data…
Abstract Number: 2996 • 2018 ACR/ARHP Annual Meeting
The Economic Burden of Systemic Lupus Erythematosus (SLE) within a Medicaid Cohort Stratified By Disease Severity
Karen Costenbader¹, Shaum Kabadi², Emily Durden³, Isabelle Winer³, Kirstin Bacani², Jinoos Yazdany⁴ and Ann E. Clarke⁵, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²AstraZeneca, Gaithersburg, MD, ³Truven Health Analytics an IBM Company, Ann Arbor, MI, ⁴University of California, San Francisco, San Francisco, CA, ⁵Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Estimates of the economic burden of SLE within economically disadvantaged populations in the US are limited. The purpose of this study is to provide…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].